Bellicum Pharmaceuticals Profile

10.41
USD 0.11  1.07%
10.21Last Month High 11.81 
10.2Trading Day  High 10.72 

Acquisition by Naeve Gregory S of 130000 shares of Bellicum Pharmaceuticals subject to Rule 16b-3

Bellicum Pharmaceuticals Inc insider trading alert for grant of employee stock option (right to buy) by Naeve Gregory S, Sr. VP Chief Business Officer, on August 23, 2017. This event was filed by Bellicum Pharmaceuticals with SEC on 2017-08-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Bellicum Pharmaceuticals Summary

Bellicum Pharmaceuticals Inc (BLCM) is traded on NASDAQ General Markets in USA. It is located in TEXAS, U.S.A and employs 72 people. Bellicum Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 339.24 M. Bellicum Pharmaceuticals Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 33.23 M outstanding shares of which 4.12 M shares are currently shorted by private and institutional investors with about 9.65 trading days to cover. Bellicum Pharmace currently holds about 130.23 M in cash with (68.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.92.
Check Bellicum Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

Top Holders

Selected Bellicum Pharmaceuticals Inc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Bellicum Pharmaceuticals Against Markets

Current Ratings  

Bellicum Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
< 13% 
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameBellicum Pharmaceuticals Inc
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock Stocks Directory
RegionNorth America
LocationTEXAS, U.S.A
Business AddressBellicum Pharmaceuticals, Inc.Houston, TX
ExchangeNASDAQ General Markets
CIK Number01358403.0
CUSIP079481107
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.bellicum.com
Contact Number832 384 1100
CurrencyUSD - US Dollar

Recommendations

Bellicum Pharmaceuticals Analyst Recommendations
Target PriceAdvice# of Analysts
28.8Buy5Odds
Bellicum Pharmaceuticals Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Bellicum Pharmaceuticals Analyst Advice  

Opportunities

Explore Investment Opportunities
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked.
Explore Investing Ideas  

Earnings

Bellicum Pharmaceuticals Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.67March 13, 2017
Bellicum Pharmaceuticals Inc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate